All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your PsOPsA Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2022-10-21T14:55:05.000Z

The safety and frequency of adverse events with spesolimab treatment

Oct 21, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new development in psoriasis.

Bookmark this article

Introduction

Dysregulation of the IL-36 pathway has been implicated in several inflammatory diseases, such as generalized pustular psoriasis (GPP), palmoplantar pustulosis, and atopic dermatitis. Spesolimab, a first-in-class anti-interleukin (IL)-36R antibody, has been shown to be efficacious and safe for the management of GGP flares.

Spesolimab was recently granted Food and Drug Administration (FDA) approval for the treatment of GPP flares, as previously reported on the Psoriasis and Psoriatic Arthritis Hub. At the 2022 European Academy of Dermatology and Venereology Congress (EADV), Mockenhaupt presented safety data from five clinical trials investigating spesolimab.1

Study design1 

The five clinical trials include a phase I trial (NCT02978690) and four phase II, double-blind, randomized placebo-controlled trials (NCT03782792; NCT03135548; NCT04015518; NCT03822832). A detailed summary of the studies is shown in Table 1. Across the five studies, 222 patients were treated with spesolimab and 100 patients received placebo.

Table 1. Study details*

Study characteristics

Study 1
(
NCT02978690)

Study 2
(NCT03782792)

Study 3
(NCT03135548)

Study 4
(NCT04015518)

Study 5
(NCT03822832)

Disease type

GPP

GPP

PPP

PPP

AD

Phase

I

II

IIa

IIb

IIa

Spesolimab
dose

10 mg/kg

900 mg

900 mg or
300 mg every 4 weeks

300 mg or
600 mg every 4 weeks

600 mg every
4 weeks

Administration
method

Intravenous

Intravenous

Intravenous

Subcutaneous

Intravenous

Total patients,
n

7

53

59

152

51

Spesolimab
treated, n

7

35

38

109

33

Placebo
treated, n

N/A

18

21

43

18

AD, atopic dermatitis; GPP, generalized pustular psoriasis; N/A, not applicable; PPP, palmoplantar pustulosis.
*Adapted from
Mockenhaupt.1
A loading dose of 1500 mg or 3000 mg was given first.

Safety1

The rate ratio of adverse events (AEs) for spesolimab versus placebo was 1.3, 0.9, 0.9, and 1.2 for studies 2, 3, 4, and 5, respectively. Adverse event occurrence, including severe and serious AEs, is shown in Figure 1; there were no patient deaths reported across the five studies. Infections were mostly mild and uncomplicated, the most common are outlined in Figure 2. Two of the placebo-controlled trials demonstrated a lower infection rate in the spesolimab group (Trial 3 and Trial 4), while two showed a lower infection rate in the placebo group (Trial 2 and Trial 5). Upper respiratory tract infections were most common but others, such as urinary tract infections, were also reported.

Figure 1. Incidence of adverse events* 

AE, adverse event.
*Adapted from Mockenhaupt.1
Rheumatology Common Toxicity Criteria ≥3.
A patient may have serious adverse events with multiple seriousness criteria.

 

Figure 2. Overall infection rate and most common infection per study* 

*Adapted from Mockenhaupt.1

Rates of hypersensitivity (eczema, rash, allergic rhinitis, and drug reaction with eosinophilia and systemic symptoms), anaphylactic reactions (including circulatory collapse), and angioedema (eye oedema and urticoria) were evaluated in Studies 2, 4, and 5. There was a similar frequency of hypersensitivity between the placebo and spesolimab groups, with the highest frequency observed in Study 5 (33.3% and 44.4% in the spesolimab and placebo arms, respectively). Eosinophil values were also measured for all five trials, there was no evidence of eosinophilia associated with spesolimab treatment. High eosinophils (>1 × 109/L) were observed in two patients (28.6%) in Study 1 and four patients in the placebo (28.6%) and four patients in the spesolimab (12.9%) arm of Study 5. For all other trials, no patients in either arm were found to have a high eosinophil count. Although elevation in liver enzymes was recorded, this was not found to be associated with spesolimab treatment.

Conclusion

Analysis of these five clinical trials showed a similar frequency of AEs between the placebo and treatment arms. Spesolimab was shown to have a favorable safety profile, with no evidence of treatment-associated eosinophilia in patients with GPP, palmoplantar pustulosis, or atopic dermatitis; however, this was in a limited number of patients. This data and its recent FDA approval suggest spesolimab could prove an effective treatment option for patients with GPP and other chronic inflammatory diseases.

  1. Mockenhaupt M. Spesolimab safety in generalized pustular psoriasis, palmoplantar pustulosis and atopic dermatitis. Oral abstract #2226. European Academy of Dermatology and Venereology Congress 2022; Sept 10, 2022; Milan, IT.

Newsletter

Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox